Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447885 | 1.00 | PLAU (0.52) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL13929740 | 1.00 | PLAU (0.52) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL24773905 | 0.90 | TSHR (0.44) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL1338448 | 0.89 | PLAU (0.46) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL385636 | 0.86 | IDO1 (0.41) | PLAUCA1CA2ANPEPMAOA | |
| SCHEMBL12472685 | 0.79 | DGAT1 (0.48) | — | |
| SCHEMBL12471417 | 0.75 | FAAH (0.50) | — | |
| SCHEMBL6157650 | 0.75 | HTR1D (0.48) | HTR1A | |
| SCHEMBL27743918 | 0.75 | HTR2A (0.43) | GRIN2B | |
| SCHEMBL27591540 | 0.75 | HTR2A (0.43) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | Life Technologies Corporation | 2024-01-04 | — | — | US | disclosed |
| US-20230380280-A1 | ORGANIC COMPOUNDS, MIXTURES AND APPLICATIONS THEREOF IN ORGANIC ELECTRONIC DEVICES | Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-3464317-B1 | AMINOSTEROID DERIVATIVES AND PROCESS FOR PRODUCING SAME | UNIV LAVAL (CA) | 2023-04-26 | — | — | EP | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| US-5135975-A | Plastic additives useful as nucleating agents for food or cosmetic containers or packaging | MILLIKEN RESEARCH CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-5049605-A | Nucleation, food or cosmetic packaging | MILLIKEN RESEARCH CORPORATION (US) | 1991-09-17 | — | — | US | disclosed |
| EP-0432694-A2 | Aminoalcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
| EP-0421634-A2 | Use of bis(3,4-dialkylbenzylidene) sorbitol acetals and of compositions containing it | MILLIKEN RESEARCH CORPORATION (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0150952-B1 | PHOTOPOLYMERIZABLE COMPOSITION | KURARAY CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
| US-4668712-A | MONOMER, PHOTOINITIATOR, DENTAL FILLINGS | KURARAY CO., LTD. (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0150952-A2 | Photopolymerizable composition | KURARAY CO., LTD. (JP) | 1985-08-07 | — | — | EP | disclosed |
| US-4060677-A | Process for molecular weight lowering of vinyl halide polymers employing saturated carbon to carbon bonded aldehydes | HOOKER CHEMICALS & PLASTICS CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | PLAU 2558/4885MTNR1A 4065/4885MTNR1B 3978/4885 |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | CHMP4B, LIPA, CETP | PLAU 2422/4885MTNR1A 3873/4885MTNR1B 3762/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | PLAU 3745/4885MTNR1A 3879/4885MTNR1B 3467/4885 |
| US-20230380280-A1 | ORGANIC COMPOUNDS, MIXTURES AND APPLICATIONS THEREOF IN ORGANIC ELECTRONIC DEVICES | OR10J3, AOX1, SLCO4C1 | PLAU 3341/4885MTNR1A 3922/4885MTNR1B 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.